奥沙利铂联合替吉奥治疗吉西他滨耐药转移性乳腺癌的疗效观察  

Efficacy of oxaliplatin combined with tegafur-gimeracil-oteracil potassium in the treatment of gemcitabine-resistant metastatic breast cancer

作　　者：魏向东 牛俊波[2] 潘宝军 WEI Xiang-dong;NIU Jun-bo;PAN Bao-jun(Breast and Thyroid Surgery,Changle People's Hospital,Shandong Weifang 262400,China;Breast and Thyroid Surgery, Shouguang People's Hospital,Shandong Weifang 262700,China)

机构地区：[1]昌乐县人民医院乳腺甲状腺外科,山东潍坊262400 [2]寿光市人民医院乳腺甲状腺外科,山东潍坊262700

出　　处：《临床医药文献电子杂志》2019年第26期7-9,共3页Electronic Journal of Clinical Medical Literature

摘　　要：目的观察转移性乳腺癌患者在吉西他滨耐药后采用奥沙利铂联合替吉奥进行治疗的疗效及安全性。方法选择符合转移性乳腺癌诊断标准的患者86例,随机分为观察组与对照组,两组开始均采用吉西他滨单药治疗。在患者对吉西他滨出现耐药后,观察组采用奥沙利铂联合替吉奥治疗,对照组只采用奥沙利铂单药治疗。在患者主动放弃,出现疾病进展或者不可耐受的毒副作用时停止治疗。治疗完成后对比两组患者的临床疗效、无进展生存期、毒副作用情况。结果两组患者的临床疗效均有所改善,观察组在治疗后临床总有效率要高于对照组患者(P<0.05);观察组的无进展生存期要明显高于对照组(P<0.05);两组患者均出现不同程度及类型的毒副作用,观察组毒副作用发生率相比对照组要小,但是差异不具有统计学意义(P<0.05)。结论奥沙利铂联合替吉奥治疗吉西他滨耐药转移性乳腺癌临床疗效确切,无进展生存期较长,可以作为临床治疗吉西他滨耐药转移性乳腺癌的新方案。Objective To observe the efficacy and safety of oxaliplatin combined with tegafur, gimeracil and oteracil potassium in patients with metastatic breast cancer after gemcitabine resistance.Methods Eighty-six patients who met the diagnostic criteria for metastatic breast cancer were randomly divided into observation group and control group.Both groups were treated with gemcitabine monotherapy.After the patient developed resistance to gemcitabine,the observation group was treated with oxaliplatin combined with tegafur,gimeracil and oteracil potassium and the control group treated with oxaliplatin monotherapy. The treatment is stopped when the patient voluntarily gives up and develops disease progression or intolerable side effects. After the treatment was completed, the clinical efficacy,progression-free survival, and side effects were compared between the two groups.Results The clinical efficacy of the two groups was improved. The total effective rate of the observation group was higher than that of the control group (P<0.05).The progression-free survival of the observation group was significantly higher than that of the control group (P<0.05).There were different degrees and types of toxic side effects in the two groups. The incidence of toxic and side effects in the observation group was smaller than that in the control group,but the difference was not statistically significant(P0.05).Conclusion Oxaliplatin combined with tegafur, gimeracil and oteracil potassium in the treatment of gemcitabine-resistant metastatic breast cancer is clinically effective, and progression free survival was longer.It can be used as a new treatment for gemcitabine-resistant metastatic breast cancer.

关 键 词：奥沙利铂 替吉奥 吉西他滨耐药 转移性乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]